Baldwin Leads 22 Colleagues in Calling on FDA to End Discriminatory Blood Donation Policy
WASHINGTON, D.C. – Today, U.S. Senator Tammy Baldwin (D-WI) led a group of her 22 colleagues in sending a letter to the Food and Drug Administration (FDA) Commissioner Dr. Robert Califf expressing support for the agency’s recent proposal to end discriminatory blood donor deferral policies for men who have sex with men (MSM) and instead follow science to assess blood donor eligibility using an individual risk-based assessment. The FDA’s proposed blood donor deferral policy eliminates time-based deferrals that had previously existed for MSM, marking an important shift to ensure that blood donation policy is not rooted in not outdated stigmas, but rather science.
In addition to Senator Baldwin, the letter was co-signed by Senators Michael Bennet (D-CO), Richard Blumenthal (D-CT), Cory Booker (D-NJ), Sherrod Brown (D-OH), Maria Cantwell (D-WA), Ben Cardin (D-MD), Bob Casey (D-PA), Christopher Coons (D-DE), Tammy Duckworth (D-IL), John Fetterman (D-PA), Kirsten Gillibrand (D-NY), Martin Heinrich (D-NM), Mazie Hirono (D-HI), Amy Klobuchar (D-MN), Robert Menendez (D-NJ), Jeff Merkley (D-OR), Alex Padilla (D-CA), Bernard Sanders (I-VT), Tina Smith (D-MN), Elizabeth Warren (D-MA), Peter Welch (D-VT), and Ron Wyden (D-OR).
Senator Baldwin has long advocated to end this discriminatory blood ban. In 2022, when the Red Cross declared its first-ever national blood supply shortage, Senator Baldwin led colleagues in urging the Biden administration to act on the most up-to-date science and increase the eligible blood donor base to help curb the crisis. In 2020, Senator Baldwin led a letter to the FDA expressing concerns with the agency’s discriminatory blood donor policy amid a nationwide shortage of donated blood resulting in the FDA shortening the deferral period for MSM from 12 months down to three months.
In 2016, Senator Baldwin led a bipartisan group of Senators in calling on the FDA to swiftly move to end the discriminatory blood donation deferral policy for MSM. In 2014, she led over 75 members of Congress in calling on the FDA to end the outdated ban and replace it by instituting a risk-based policy.
Full text of the letter is available here.
An online version of this release is available here.
NOTE: This press release was submitted to Urban Milwaukee and was not written by an Urban Milwaukee writer. While it is believed to be reliable, Urban Milwaukee does not guarantee its accuracy or completeness.
Mentioned in This Press Release
Recent Press Releases by U.S. Sen. Tammy Baldwin
Senator Baldwin Helps Secure Over $38 Million Investment in Wisconsin Commuter Rail Service
Jan 9th, 2025 by U.S. Sen. Tammy BaldwinFunding will support Amtrak Borealis service from Chicago to Minneapolis via Milwaukee, Wisconsin Dells, La Crosse and more through 2029
Baldwin Delivers $25 Million to Improve Road Safety Along National Avenue in Milwaukee
Jan 9th, 2025 by U.S. Sen. Tammy BaldwinFunding through Baldwin-backed Bipartisan Infrastructure Law will improve bike and pedestrian safety, reduce car speeds, and boost public transit
Baldwin-Led Legislation to Place Women’s Suffrage National Monument on National Mall Signed into Law
Jan 6th, 2025 by U.S. Sen. Tammy BaldwinLegislation authorizes the first ever monument dedicated to women’s history to be built on the National Mall in Washington, D.C.